<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (aPL) and <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) have been described in primary <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sjögren's syndrome</z:e> (pSS) with controversial findings regarding aPL prevalence and their association with thrombotic events </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated 100 consecutive pSS patients (American-European criteria) and 89 age-gender-ethnicity-matched healthy controls for IgG/IgM anticardiolipin (aCL), IgG/IgM anti-beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi>-I (aβ2GPI), and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA) (positivity according to APS Sydney's criteria) </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical analysis followed standardized interview and physical examination assessing thrombotic and nonthrombotic APS manifestations and <z:mp ids='MP_0005048'>thrombosis</z:mp> risk factors </plain></SENT>
<SENT sid="3" pm="."><plain>aPLs were detected in 16 % patients and 5.6 % controls (p = 0.035) </plain></SENT>
<SENT sid="4" pm="."><plain>LA was the most common aPL in patients (9 %), followed by aβ2GPI (5 %) and aCL (4 %) </plain></SENT>
<SENT sid="5" pm="."><plain>Thrombotic events occurred in five patients [<z:hpo ids='HP_0001297'>stroke</z:hpo> in two, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> in one and <z:hpo ids='HP_0002625'>deep-vein thrombosis</z:hpo> (DVT) in four], but in none of controls (p = 0.061) </plain></SENT>
<SENT sid="6" pm="."><plain>Mean age at time of <z:hpo ids='HP_0001297'>stroke</z:hpo> was 35 years </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients with thrombotic events (including the two with <z:hpo ids='HP_0001297'>stroke</z:hpo>) had APS (Sydney's criteria) and were positive exclusively for LA </plain></SENT>
<SENT sid="8" pm="."><plain>Comparison of patients with (n = 16) and without (n = 84) aPL revealed similar mean age, female predominance, and ethnicity (p &gt; =0.387) </plain></SENT>
<SENT sid="9" pm="."><plain>Frequencies of <z:hpo ids='HP_0000965'>livedo reticularis</z:hpo> (25 vs. 4.8 %, p = 0.021), <z:hpo ids='HP_0001297'>stroke</z:hpo> (12.5 vs. 0 %, p = 0.024), and DVT (18.8 vs. 1.2 %, p = 0.013) were significantly higher in APL + patients </plain></SENT>
<SENT sid="10" pm="."><plain>Conversely, frequencies of <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0001513'>obesity</z:hpo>, smoking, sedentarism, and hormonal contraception were similar in patients with or without aPL (p ≥ 0.253) </plain></SENT>
<SENT sid="11" pm="."><plain>Our study identified LA as an important marker for APS in pSS, particularly for <z:hpo ids='HP_0001297'>stroke</z:hpo> in young patients, warranting routine evaluation of these antibodies and rigorous intervention in modifiable risk factors </plain></SENT>
</text></document>